Effectiveness of growth hormone in promoting endometrial growth in patients with endometrial dysplasia in frozen embryo transfer.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of endometriosis.

This study was designed to investigate the effect of growth hormone (GH) in promoting endometrial thickness, blood flow, and pregnancy outcome in patients with thin endometrium for frozen embryo transfer.

Why It Was Studied

The patients were randomly divided into the GH injection group (19 cases, endometrium preparation with hormone replacement therapy (HRT) and GH by subcutaneous injection) and the control group (19 cases, endometrium preparation with HRT).

Both groups were similar in socio-demographic characteristics.

Who Took Part

PubMed tags the participants as women only.

Thirty-eight patients were recruited in the reproductive center of Jingzhou Hospital affiliated to Yangtze University who cancelled fresh embryo transfer due to thin endometrium and planned to undergo frozen-thawed embryo transfer (FET) from May 2019 to May 2020.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

The subject headings attached to it are Embryo Implantation, Growth Hormone, Pregnancy Outcome, Pregnancy Rate, Endometrium and Embryo Transfer.

Author keywords: endometrial dysplasia.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in people with endometriosis.

The publication is from 2023 (African journal of reproductive health), a journal based in Nigeria.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Endometriosis research.